Viking Therapeutics (VKTX) Current Assets (2014 - 2026)

Viking Therapeutics has disclosed Current Assets across 13 years of filings, most recently posting $608.2 million for Q1 2026.

• Current Assets for Q1 2026 came in at $608.2 million, down 29.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $608.2 million (down 29.77% YoY), and the FY2025 annual result was $715.6 million, down 21.12% from the prior year.
• Current Assets came in at $608.2 million for Q1 2026 at Viking Therapeutics, down from $715.6 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $966.3 million in Q1 2024 to a low of $149.5 million in Q1 2023.
• The 5-year median for Current Assets is $608.2 million (2026), against an average of $559.7 million.
• Across the five-year window, Current Assets jumped 546.52% in 2024 and decreased 29.77% in 2026, its largest moves.
• Viking Therapeutics' Current Assets stood at $167.0 million in 2022, then jumped by 119.84% to $367.2 million in 2023, then surged by 147.05% to $907.2 million in 2024, then decreased by 21.12% to $715.6 million in 2025, then fell by 15.01% to $608.2 million in 2026.
• The last three Current Assets figures came in at $608.2 million (Q1 2026), $715.6 million (Q4 2025), and $738.7 million (Q3 2025), per Business Quant data.